As of this writing, GeneDx (WGS) inventory has plummeted 39.3% in morning buying and selling after the corporate reported its first-quarter earnings outcomes that beat expectations however failed to satisfy buyers’ lofty hopes.
GeneDx is a well being intelligence firm specializing in exome and genome testing for genetic illness prognosis. The corporate’s platform helps display screen sufferers’ DNA for numerous illnesses, making it a lovely funding alternative for these within the healthcare sector.
In its Q1 earnings report, GeneDx introduced income of $87.1 million, which was 10% above forecasts however not sufficient to fulfill buyers who have been anticipating a extra substantial beat. The corporate’s take a look at quantity declined sequentially for the primary time since going public, with exome and genome exams rising 24% year-over-year to twenty,562.
Regardless of this decline in take a look at volumes, GeneDx managed to lift its steerage for the 12 months, projecting $360 million to $375 million in gross sales, which tops Avenue projections of $358.9 million. Nevertheless, buyers have been seemingly anticipating a extra vital enhance given the corporate’s robust progress prospects.
The inventory had run up six straight days heading into the report however in the end fell again down after failing to satisfy expectations. As of this writing, GeneDx shares are buying and selling at 70.97, considerably decrease than their earlier shut of $116.97.
In accordance with Finviz information, GeneDx’s institutional possession is comparatively excessive, with notable buyers together with Casdin Capital, Corvex Administration LP, and Goldman Sachs Group Inc., amongst others. The corporate has additionally seen vital insider buying and selling exercise in latest months, with executives Kevin Feeley and Katherine Stueland promoting shares.
GeneDx operates as a well being intelligence firm utilizing its collected illness information units to offer exome and genome testing for prognosis of genetic illnesses. With the rising demand for personalised drugs and genomics analysis, GeneDx is well-positioned to capitalize on this pattern.
Whereas buyers could also be dissatisfied with the Q1 earnings report, it’s important to think about the broader context of the corporate’s progress prospects and steerage increase. As a well being intelligence firm, GeneDx has vital potential for long-term progress, pushed by its progressive method to genetic illness prognosis.
Key Takeaways:
- GeneDx reported Q1 income of $87.1 million, beating expectations however failing to satisfy buyers’ hopes.
- The corporate’s take a look at quantity declined sequentially for the primary time since going public, with exome and genome exams rising 24% year-over-year to twenty,562.
- Regardless of this decline in take a look at volumes, GeneDx raised its steerage for the 12 months, projecting $360 million to $375 million in gross sales.
Need to keep forward of market developments?
Enroll now for our free each day inventory alerts. Simply faucet right here.
By becoming a member of our neighborhood, you’ll achieve entry to unique insights and evaluation on the newest market developments. Don’t miss out – join now!
